
n=219 patients
with phenotype oligoarthritis or polyarthritis
at baseline
n=36 patients did not start
with MTX monotherapy
n=183 patients start MTX monotherapy
within 6 months of their diagnosis
n=93 patients switched/stopped
MTX monotherapy
n=90 patients continue MTX monotherapy
until 12 months after diagnosis
n=23 patients used
MTX monotherapy intermittently
n=48 MDA or EULAR remission
and MDA joint criteria at T6 and T12*
n=25 patients switched
to another DMARD
n=29 MDA or EULAR remission
at T6
n=45 patients another
DMARD was added
n=13 no MDA or EULAR remission
at T6
n=83 non-responders
to MTX monotherapy
n=48 responders
to MTX monotherapy
n=51 patients excluded:
n=28 switched before T3
n=5 switched due
to side effects
n=18 serum samples
were missing
n=21 patients excluded:
n=11 used
concomitant steroids
n=10 serum samples
were missing
n=32 definite non-responders
to MTX monotherapy
n=27 definite responders
to MTX monotherapy